Target Name: CD6
NCBI ID: G923
Other Name(s): CD6 variant 2 | Soluble CD6 | T-cell differentiation antigen CD6 | TP120 | T-cell differentiation antigen CD6 (isoform 2) | CD6 variant 1 | T12 | CD6 molecule, transcript variant 1 | CD6_HUMAN | T-cell differentiation antigen CD6 (isoform 1) | CD6 molecule, transcript variant 2 | CD6 molecule | CD6 antigen

CD6: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

CD6 is a viral envelope protein that is present in the cytoplasm of many types of human cells, including immune cells and epithelial cells. It is a key component of the immune response and has been implicated in various diseases, including cancer, autoimmune disorders, and chronic obstructive pulmonary disease (COPD). In this article, we will explore CD6 as a potential drug target and biomarker for multiple chronic diseases.

CD6's Involvement in Diseases

CD6 has been associated with the development and progression of various diseases, including cancer. Studies have shown that CD6 levels are often elevated in cancer cells compared to healthy cells, and that inhibiting CD6 has been shown to have anti-tumor effects. This is because CD6 plays a role in the development of cancer stem cells, which are cancer-promoting cells that can give rise to new tumors.

In addition to its role in cancer, CD6 has also been linked to the development of autoimmune disorders. Many autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, involve an overactive immune response that attacks the body's own tissues. CD6 has been shown to be involved in the regulation of immune cell function and has been implicated in the development of these disorders.

CD6's Role in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is characterized by airflow obstruction and chronic inflammation of the airways. COPD has a high prevalence among smokers and is a leading cause of morbidity and mortality worldwide. CD6 has been shown to be involved in the development and progression of COPD, and has been shown to be a potential biomarker for this disease.

One of the hallmarks of COPD is the recruitment of immune cells to the airways, which can cause chronic inflammation and tissue damage. CD6 has been shown to be involved in the regulation of immune cell function and has been implicated in the development of COPD. Studies have shown that individuals with COPD are more likely to have increased levels of CD6 in their airways compared to individuals without COPD.

CD6 as a Potential Drug Target

CD6 has been shown to be involved in various diseases, including cancer, autoimmune disorders, and COPD. As a result, CD6 has emerged as a potential drug target for the treatment of these diseases.

CD6 has been shown to be involved in the regulation of cell proliferation and has been linked to the development of cancer. inhibiting CD6 has been shown to have anti-tumor effects. Therefore, drugs that inhibit CD6 expression have been shown to have potential anti-cancer properties.

In addition to its role in cancer, CD6 has also been linked to the development of autoimmune disorders. Therefore, drugs that target CD6 have been shown to have potential autoimmune disorders.

CD6 has also been shown to be involved in the regulation of inflammation and has been linked to the development of chronic obstructive pulmonary disease (COPD). Therefore, drugs that target CD6 have been shown to have potential COPD treatments.

Conclusion

CD6 has been shown to be involved in various diseases, including cancer, autoimmune disorders, and COPD. As a result, CD6 has emerged as a potential drug target for the treatment of these diseases. The inhibition of CD6 expression has been shown to have anti-tumor, anti-immune, and anti-inflammatory effects, making it a promising target for the development of new drugs. Further research is needed to fully understand the role of CD6 in diseases and to develop safe and effective drugs that target CD6.

Protein Name: CD6 Molecule

Functions: Cell adhesion molecule that mediates cell-cell contacts and regulates T-cell responses via its interaction with ALCAM/CD166 (PubMed:15048703, PubMed:15294938, PubMed:16352806, PubMed:16914752, PubMed:24945728, PubMed:24584089). Contributes to signaling cascades triggered by activation of the TCR/CD3 complex (PubMed:24584089). Functions as costimulatory molecule; promotes T-cell activation and proliferation (PubMed:15294938, PubMed:16352806, PubMed:16914752). Contributes to the formation and maturation of the immunological synapse (PubMed:15294938, PubMed:16352806). Functions as calcium-dependent pattern receptor that binds and aggregates both Gram-positive and Gram-negative bacteria. Binds both lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria (PubMed:17601777). LPS binding leads to the activation of signaling cascades and down-stream MAP kinases (PubMed:17601777). Mediates activation of the inflammatory response and the secretion of pro-inflammatory cytokines in response to LPS (PubMed:17601777)

More Common Targets

CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8